RCT | Small benefit from pembrolizumab + gemcitabine/cisplatin vs. gemcitabine/cisplatin alone in advanced biliary tract cancer

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

News Release: First-line Pembrolizumab Plus Chemotherapy May Benefit Patients with Advanced Biliary Tract Cancers – American Association for Cancer Research

Commentary on Twitter

New @TheLancet – Kelley et al – Pembrolizumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966)https://t.co/ZbdRQwzSuW#gitwitter #onctwitter pic.twitter.com/PwoNAduQxK

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) April 18, 2023